Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tisagenlecleucel vs Standard of Care in Relapsed/Refractory Aggressive B-cell NHL
NCT03570892Phase 3Completed
- Sponsor
- Novartis
- Start
- May 2019
- Primary completion
- May 2021
- Modality
- CAR-T Cells
- Countries
- 18
01
Overview
A Phase 3 trial of tisagenlecleucel in non-Hodgkin lymphoma (NHL), sponsored by Novartis. Started May 2019; status: completed.
02
Drugs
tisagenlecleucel
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT03570892.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03570892.